NewCardio, Inc. (NWCI) Stock

About NewCardio, Inc.

NewCardio, Inc. is a company dedicated to cardiac diagnostics and related services. Its primary objective is the research, creation, and market introduction of exclusive software platform technologies. These innovations are designed for two main applications: the non-invasive diagnosis and continuous monitoring of cardiovascular diseases (CVD), and the assessment of cardiac safety for experimental drugs. The company's underlying technology analyzes the heart's electrical activity in real-time and in three dimensions, using data gathered from the body's surface via standard 12-lead electrocardiogram (ECG) electrodes. NewCardio is also actively developing several products. QTinno, for instance, is an automated solution for cardiac safety, utilizing algorithms to automatically measure, analyze, and report on collected ECGs, thereby streamlining traditional manual or semi-automated methods. Another product, CardioBip, is a mobile ECG system for remote transmission, comprising a portable recording and transmitting device along with web-based software that receives, processes, and interprets the data. Furthermore, the company is progressing with my3KG, a software application intended to provide a comprehensive method for evaluating cardiac electrical activity across both time and space. NewCardio, Inc. was founded in 2004 and is headquartered in Branchburg, New Jersey.

NewCardio, Inc. (NWCI) stock trades at $0.00 with a market capitalization of $3315. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.01. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, NewCardio, Inc. generates a return on equity (ROE) of 366.67% — well above the market average, a sign of a high-quality business, return on capital employed of 900.00%, an operating margin of -15765.37%, a net profit margin of 0.00%.

Official website: www.newcardio.com